Corporate Accountability Report Index-Summary

HEALTH CARE

– Accredo Health, Ernst & Young audit, misleading statements, no scienter (6th Cir.), 1059
– Aetna, misstatements to conceal underpricing to gain market share (3d Cir.), 922
– AHERF collapse, PricewaterhouseCoopers, in pari delicto defense availability (Pa.), 206; vacated (3d Cir.), 604; defense narrows, BNA Insights, 748
– Airborne Health acquisition of Squid Soap, failure to disclose litigation claim (Del. Ch. Ct.), 855
– Alcon Inc. class claims against Novartis, jurisdiction (S.D.N.Y.), 575; amended complaint denied, 770
– Am. Med. Ass'n, SOX jurisdiction (7th Cir.), 328
– Amgen Inc. “stock drop,” off-label drug uses (C.D. Cal.), 250
– Amylin Pharmaceuticals, attorneys' fees for disabling continuing directors debt instrument provisions (Del. Ch.), 1292
– Biovail accounting fraud, SEC summary judgment attempt (S.D.N.Y.), 655
– Boston Scientific, scienter in stent fraud case (D. Mass.), 499
– Bristol-Myers Squibb, revenue recognition scheme, former executives defer prosecution (D.N.J.), 710
– Cephalon marketing practices oversight problem, no presuit demand futility (3d Cir.), 1377
– Cutera revenue projections protected as forward looking (9th Cir.), 739
– Executive compensation, insurance providers, limits, BNA Insights, 664
– Express Scripts, supporting facts lacking in misrepresentation class action (E.D. Mo.), 737
– Fischer Imaging, aiding and abetting claims against sales official (D. Conn.), 769
– Hansen Medical revenue recognition derivative suit, presuit demand futility not shown (N.D. Cal.), 824; amended complaint fails on same grounds, 1295
– HealthSouth SEC Fair Fund distribution, 825
– Instrumentation Laboratories, SOX preclusion by ALJ ruling (4th Cir.), 13
– Matrixx Initiatives, rare Zicam adverse reaction disclosure, fraud claim (U.S., rev grant), 623; statistically insignificant adverse events as basis for claim, amicus briefs, 954; NASAA, AARP support investors in amicus briefs, 1256
– McKessonHBOC, revenue recognition scheme, former chairman sentenced (N.D. Cal.), 277; former executive sentenced, 468
– Medicis Pharmaceutical, scienter in product return reserves GAAP violations (D. Ariz.), 48
– Medivation, shareholder making presuit demand different from one filing short-swing suit (S.D.N.Y.), 1144
– Medtronics, misleading statements about recalled device, no scienter (8th Cir.), 1060
– Merck Vioxx suit, statute of limitations, scienter discovered (U.S.), 434; statute of limitations defense in securities cases harder to assert, BNA Insights, 690
– Newland Pharmacy, failure to honor right of first refusal in stock sale (Cal. Ct. App.), 69
– Omnicare loss causation, U.S. asked to file brief (U.S., rev sought), 1114; (rev den), 1230; amicus brief filed in investors' suit, 1320
– Perrigo, auction rate securities misstatement case proceeds (S.D.N.Y.), 1175
– Pharmacia, Pfizer, Celebrex misrepresentations (U.S., rev den), 496
– QuadraMed merger, injunction sought by preferred shareholder (Del. Ch.), 327
– Rigel Pharmaceuticals, false and misleading statements in disclosures (N.D. Cal.), 49
– Rite Aid executive, resentencing after Booker (3d Cir.), 249
– Schering-Plough

– – Class action settles (D.N.J.), 42
– – ERISA “stock drop,” presumption of prudence overcome (D.N.J.), 715; court approves settlement, 1382
– – Inspection of minutes limited (N.J. Super. Ct.), 951

– WellCare Health Plans, withheld funds included as revenue, class settlement (M.D. Fla.), 856

HEDGE FUNDS

– Basis Yield Alpha Fund says Goldman Sachs claim meets Morrison (S.D.N.Y.), 955
– Galleon Mgmt. insider trading case, DOJ inadvertently gives wiretap evidence to SEC (S.D.N.Y.), 124; timing of criminal and civil trials, 170; wiretap evidence order stayed (2d Cir.), 172; SEC urges no stay, 202; defendants respond, 221; case shows DOJ and SEC insider trading trends, 300; stay ordered pending appeal (2d Cir.), 328; judge wants more information on proposed Schottenfeld settlement (S.D.N.Y.), 348; amicus filings, 467; Schottenfeld settlement approved, 469; suppression of wiretap evidence sought, 499; leaks of confidential information under investigation, 543; fairness requires disclosure to both sides, says SEC (2d Cir.), 546; oral argument set, 598; extension granted to DOJ for opposition to motion (S.D.N.Y.), 656; DOJ says wiretaps appropriate (S.D.N.Y.) and SEC tries to prevent amicus filing (2d Cir.), 718; DOJ omissions from affidavit, hearing set (S.D.N.Y.), 885; remand for balancing test of need and privacy (2d Cir.), 1090; defendant claims DOJ should have disclosed SEC investigation (S.D.N.Y.), 1142; Goel settles, 1230; separate trials for Rajaratnam and Chiesi allowed, 1299; SEC renews request for wiretap evidence, 1382
– PricewaterhouseCoopers fraud claim for audit, dismissal (N.Y.), 720
– SEC enforcement policy, 2009 developments, BNA Insights, 355